• Explore /
  • Poster
  • / Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451).

Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451).

Abstract Poster

Authors

null

Elisabeth I. Heath

Karmanos Cancer Institute, Detroit, MI

Elisabeth I. Heath , Heather Dorothy Mannuel , Glenn Liu , Primo Lara Jr., J. P. Monk III, Thomas W. Flaig , Amado J. Zurita , Ulka N. Vaishampayan , Philip J. Stella , Daryn W. Smith , Kimberlee Dobson , Arif Hussain , Anas Al-Janadi , S. Percy Ivy , Lance K. Heilbrun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00527124

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 38)

DOI

10.1200/jco.2013.31.6_suppl.38

Abstract #

38

Poster Bd #

C11

Abstract Disclosures

Similar Posters

First Author: Reeta Barua

First Author: Munjid Al Harthy

First Author: Shahneen Kaur Sandhu

First Author: Carlo Buonerba